Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Janessa Pickering

Senior Research Fellow (currently HOT NORTH Early Career Fellow)

BSc PhD

janessa.pickering@telethonkids.org.au

+61 8 6319 1029

Dr Janessa Pickering is a research microbiologist with expertise in the molecular diagnostics and host pathogen interactions of upper respiratory tract pathogens that cause disease in children. Her PhD investigated the molecular microbiology of middle ear infection (UWA) and she has since worked in several postdoctoral roles at The Kids Research Institute Australia.

Dr Pickering joined the Skin Health team in 2019 as an WAHTN Early Career Fellow to develop laboratory diagnostics for Strep A. Her research is focussed on the colonisation and infection of Strep A in paediatric populations, and her research intersects with the large cohort and clinical trials occurring in the Skin Health, Australian Strep A Vaccine Initiative and Rheumatic Heart Disease teams.

Dr Pickering completed the Stanford Bio-Design course in 2016 and she maintains an interest in research commercialisation, particularly technologies enabling diagnostic solutions in resource-poor settings.

Projects

Koolungar (Children) Moorditj (Strong) Healthy Skin

The Koolungar (children) Moorditj (strong) Healthy Skin project is the first ever co-designed research-service Australian study to describe skin health in urban-living Aboriginal koolungar.

Improved diagnosis, treatment and prevention of recurrent tonsillitis

The Missing Piece Surveillance Study: A surveillance study for strep A pharyngitis and impetigo in the Kimberley, Australia

The Missing Piece Surveillance Study is a prospective surveillance study to determine the concurrent burden of skin and throat infections in children, from two remote communities in Northern Australia.

Science of the swab: optimising Strep A typing from clinical samples

Optimisation of sampling for a new Skin Microbiome assay

Development of molecular tools for accurate diagnosis and disease surveillance (including vaccine impact)

Published research

Searching for Strep A in the clinical environment during a human challenge trial: a sub-study protocol

Streptococcus pyogenes (also known as group A Streptococcus , Strep A) is an obligate human pathogen with significant global morbidity and mortality. Transmission is believed to occur primarily between individuals via respiratory droplets, but knowledge about other potential sources of transmission via aerosols or the environment is limited. Such knowledge is required to design optimal interventions to control transmission, particularly in endemic settings.

The role of children in transmission of SARS-CoV-2 variants of concern within households: an updated systematic review and meta-analysis, as at 30 June 2022

Meta-analyses and single-site studies have established that children are less infectious than adults within a household when positive for ancestral SARS-CoV-2. In addition, children appear less susceptible to infection when exposed to ancestral SARS-CoV-2 within a household. The emergence of SARS-CoV-2 variants of concern (VOC) has been associated with an increased number of paediatric infections worldwide.

A pilot study to develop assessment tools for Group A Streptococcus surveillance studies

Group A Streptococcus (GAS) causes pharyngitis (sore throat) and impetigo (skin sores) GAS pharyngitis triggers rheumatic fever (RF) with epidemiological evidence supporting that GAS impetigo may also trigger RF in Australian Aboriginal children. Understanding the concurrent burden of these superficial GAS infections is critical to RF prevention. This pilot study aimed to trial tools for concurrent surveillance of sore throats and skins sore for contemporary studies of RF pathogenesis including development of a sore throat checklist for Aboriginal families and pharynx photography.

Standardization of Epidemiological Surveillance of Group A Streptococcal Pharyngitis

Pharyngitis, more commonly known as sore throat, is caused by viral and/or bacterial infections. Group A Streptococcus (Strep A) is the most common bacterial cause of pharyngitis. Strep A pharyngitis is an acute, self-limiting disease but if undertreated can lead to suppurative complications, nonsuppurative poststreptococcal immune-mediated diseases, and toxigenic presentations.

Standardization of Epidemiological Surveillance of Invasive Group A Streptococcal Infections

Invasive group A streptococcal (Strep A) infections occur when Streptococcus pyogenes, also known as beta-hemolytic group A Streptococcus, invades a normally sterile site in the body. This article provides guidelines for establishing surveillance for invasive Strep A infections. The primary objective of invasive Strep A surveillance is to monitor trends in rates of infection and determine the demographic and clinical characteristics of patients with laboratory-confirmed invasive Strep A infection, the age- and sex-specific incidence in the population of a defined geographic area, trends in risk factors, and the mortality rates and rates of nonfatal sequelae caused by invasive Strep A infections.

Standardization of Epidemiological Surveillance of Group A Streptococcal Impetigo

Impetigo is a highly contagious bacterial infection of the superficial layer of skin. Impetigo is caused by group A Streptococcus (Strep A) and Staphylococcus aureus, alone or in combination, with the former predominating in many tropical climates. Strep A impetigo occurs mainly in early childhood, and the burden varies worldwide. It is an acute, self-limited disease, but many children experience frequent recurrences that make it a chronic illness in some endemic settings.

Host-dependent resistance of Group A Streptococcus to sulfamethoxazole mediated by a horizontally-acquired reduced folate transporter

Described antimicrobial resistance mechanisms enable bacteria to avoid the direct effects of antibiotics and can be monitored by in vitro susceptibility testing and genetic methods. Here we describe a mechanism of sulfamethoxazole resistance that requires a host metabolite for activity.

Roadmap to incorporating group A Streptococcus molecular point-of-care testing for remote Australia: a key activity to eliminate rheumatic heart disease

Missing Piece Study protocol: Prospective surveillance to determine the epidemiology of group A streptococcal pharyngitis and impetigo in remote Western Australia

Group A β-haemolytic Streptococcus (GAS), a Gram-positive bacterium, causes skin, mucosal and systemic infections. Repeated GAS infections can lead to autoimmune diseases acute rheumatic fever (ARF) and rheumatic heart disease (RHD). Aboriginal and Torres Strait Islander peoples in Australia have the highest rates of ARF and RHD in the world.

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.

A Meta-analysis on the Role of Children in Severe Acute Respiratory Syndrome Coronavirus 2 in Household Transmission Clusters

The role of children in the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains highly controversial. To address this issue, we performed a meta-analysis of the published literature on household SARS-CoV-2 transmission clusters (n = 213 from 12 countries). Only 8 (3.8%) transmission clusters were identified as having a pediatric index case.

Performance and Practicality of a Rapid Molecular Test for the Diagnosis of Strep A Pharyngitis in a Remote Australian Setting

Over 5 days, 120 schoolchildren from two schools in the remote Kimberley region of Australia were screened for Strep A pharyngitis. Molecular point-of-care testing identified Strep A pharyngitis in 13/18 (72.2%) symptomatic children. The portability and feasibility of molecular point-of-care testing was highly practical for remote settings.

Nasal delivery of a commensal Pasteurellaceae species inhibits nontypeable Haemophilus influenzae colonisation and delays onset of otitis media in mice

We have demonstrated that a single dose of a closely related commensal can delay onset of NTHi otitis media in vivo

Education and Qualifications

​BSc (Biomedical Science), UWA

First Class Honours Microbiology, University of Western Australia

PhD

Awards and Honours
  • Hot North Early Career Fellow, NHMRC Improving Health Outcomes in the Tropical North: A multidisciplinary Collaboration (2020)
  • The Kids Research Institute Australia Emerging Leaders Program (2020)
  • Inaugural Western Australian Health Translation Network Early Career Fellow (2019)
  • State Finalist, FameLab science communication competition: Preventing sore throats in kids (2019)
  • World Society of Paediatric Infectious Diseases early career workshop (2019)
  • Allegra Scafidas Development Award (2019)
  • Princeton University Philanthropic travel award, 17th Annual microbial ecology conference (2019)
  • Wesfarmer’s Centre for Vaccines and Infectious Diseases training scholarship (2017)
  • Most Innovative Research, Wesfarmer’s Centre for Vaccines and Infectious Diseases research retreat (2017)
  • Friends of The Kids Research Institute Australia Collaboration award, (2017)
  • Friends of The Kids Research Institute Australia International travel funding (2015)
  • OMOZ 2014 National Travel Award (2014)
  • Princess Margaret Hospital Foundation Competitive PhD Scholarship (2012-2015)
  • UWA Top Up Scholarship (2011-2015)
  • Australian Post-graduate Award Scholarship (2011-2015)
  • WA Branch Award Australian Society Microbiology (2012)
  • School of Paediatric and Child Health Best Oral Presentation, Child and Adolescent Health Symposium, Princess Margaret Hospital (2011)
  • University of Western Australia Travel Award (2011)
  • GSK Travel Award, World Society for Paediatric Infectious Diseases (2011)
Key collaborations

Mark Davies - The Peter Doherty Institute for Infection and Immunity, Melbourne

Catherine Satzke - Murdoch Children’s Research Institute

Kirsty Short - University of Queensland